Nexentis Technologies closed at $0.54 on Nov 4, down 5.50%, within 2.6% of its lowest close since Feb 26. Volume of 32.4K shares was 0.03× its 20-day average (below normal).
Split-adjusted performance: -61.3% over one month.
Short interest was 61.3K shares at the Oct 15 settlement, up 62.4% from the prior report (2.5% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NXTSNexentis Technologies | $0.5377 | −5.50% | — | — | — | — | $781.5K | |
| DCOYDecoy Therapeutics | $1.14 | +2.25% | −81.1% | — | −1042.8% | — | $743.6K | Compare |
| VBIOValion Bio | $0.5004 | −5.75% | — | — | — | — | $1.0M | Compare |
| JAGXJaguar Health | $0.4665 | −16.32% | −97.8% | −58.9% | −1036.8% | — | $1.1M | Compare |
| MTNBMatinas BioPharma Holdings | $1.19 | +3.95% | −88.4% | — | — | — | $1.2M | Compare |
| ARTLArtelo Biosciences | $2.30 | −4.17% | −90.8% | — | — | — | $1.3M | Compare |
| LABTLakewood-Amedex Biotherapeutics | $0.1850 | −5.13% | — | — | — | — | $438.4K | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1642 | +0.06% | −90.0% | −100.0% | — | — | $1.5M | Compare |
| ELABPMGC Holdings | $2.04 | +5.15% | −90.4% | — | −225.1% | — | $1.7M | Compare |
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
